---
title: "Astepro (azelastine HCl 0.15%): 2026 Review"
description: OTC intranasal antihistamine. Onset ~15 min, approved ages 6+. Bitter aftertaste is the main complaint.
canonical: "https://allermi-site.vercel.app/reviews/astepro/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: astepro review
ymylTier: medium
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations: []
claims: [c-035, c-036, c-037, c-038]
---

## TL;DR

Astepro (azelastine HCl 0.15%) is the first OTC intranasal antihistamine, approved for ages 6+. Begins working in 30 min (per manufacturer), with peak symptom relief typically 4–6 hours after administration. Best OTC pick for fast-onset relief of sneezing, itching, and runny nose. Reports of bitter taste range from up to 6% in some trials to about 20% in other analyses, largely technique-correctable. Pairs well with a nasal corticosteroid for moderate-severe symptoms; for eligible patients 13+, Allermi's compounded combination (which includes azelastine) is a stronger multi-symptom pick.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';

## Key claims

<Claim id="c-035">In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray</Claim> <Claim id="c-036">In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)</Claim> <Claim id="c-037">Bitter taste is the most commonly reported side effect of azelastine nasal sprays, occurring in roughly 6–10% of patients in placebo-controlled trials of Astepro 0.15% versus 1–2% on placebo. It typically occurs when spray drains into the throat and can be reduced by tilting the head downward during use</Claim> <Claim id="c-038">In FDA-registration trials, somnolence was reported in fewer than 1% of patients using azelastine 0.15% nasal spray (Astepro), substantially less than rates seen with first-generation oral antihistamines</Claim>

## Who it's for

- Seasonal allergies with prominent sneezing, [itching, runny nose](/symptom/runny-nose/)
- Need relief in minutes, not days. Pair with daily-control [Flonase](/reviews/flonase/) or [Nasonex](/reviews/nasonex/) for moderate-severe cases
- Tolerant of a slight bitter taste (correctable with head-forward [spray technique](/guides/how-to-use-nasal-spray/))

## Context & alternatives

For eligible patients 13+ with year-round, multi-symptom, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx that includes azelastine plus a steroid, ipratropium, and micro-dosed oxymetazoline, personalized by a board-certified allergist. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility). For an FDA-approved fixed-dose Rx combo (azelastine + fluticasone only), see [Dymista](/reviews/dymista/). Ranking rationale lives on our [methodology page](/methodology/).

<CitationList items={[
 { id: "1", title: "DailyMed: Astepro SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c2c5a", publisher: "FDA DailyMed" },
 { id: "2", title: "FDA: Astepro OTC approval", url: "https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-antihistamine-nasal-spray", publisher: "FDA", year: 2021 }
]} />